Identification of novel AKT1 inhibitors from Sapria himalayana bioactive compounds using structure-based virtual screening and molecular dynamics simulations
Open Access
- 7 March 2024
- journal article
- research article
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 24 (1) , 1-22
Abstract
Through the experimental and computational analyses, the present study sought to elucidate the chemical composition and anticancer potential of Sapria himalayana plant extract (SHPE). An in vitro analysis of the plant extract was carried out to determine the anticancer potential. Further, network pharmacology, molecular docking, and molecular dynamic simulation were employed to evaluate the potential phytochemical compounds for cervical cancer (CC) drug formulations. The SHPE exhibited anti-cancerous potential through inhibition properties against cancer cell lines. The LC-MS profiling showed the presence of 14 compounds in SHPE. Using network pharmacology analysis, AKT1 (AKT serine/threonine kinase 1) is identified as the possible potential target, and EGFR (Epidermal Growth Factor Receptor) is identified as the possible key signal pathway. The major targets were determined to be AKT1, EGFR by topological analysis and molecular docking. An in silico interaction of phytoconstituents employing molecular docking demonstrated a high binding inclination of ergoloid mesylate and Ergosta-5,7,9(11),22-tetraen-3-ol, (3.beta.,22E)- with binding affinities of -15.5 kcal/mol, and -11.3 kcal/mol respectively. Further, MD simulation and PCA analyses showed that the phytochemicals possessed significant binding efficacy with CC protein. These results point the way for more investigation into SHPE compound’s potential as CC treatment. Graphical AbstractKeywords
This publication has 50 references indexed in Scilit:
- Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agentsBiomedicine & Pharmacotherapy, 2022
- Computational identification of 2,4-disubstituted amino-pyrimidines as L858R/T790M-EGFR double mutant inhibitors using pharmacophore mapping, molecular docking, binding free energy calculation, DFT study and molecular dynamic simulationIn Silico Pharmacology, 2021
- Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysisMolecular Genetics & Genomic Medicine, 2020
- Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and ProspectiveChinese Journal of Integrative Medicine, 2019
- Sapria HimalayanaResonance, 2018
- SwissParam: A fast force field generation tool for small organic moleculesJournal of Computational Chemistry, 2011
- Natural products as leads to anticancer drugsClinical and Translational Oncology, 2007
- Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinomaInternational Journal of Cancer, 2007
- LINCS: A linear constraint solver for molecular simulationsJournal of Computational Chemistry, 1997
- Solvent accessible surface area and excluded volume in proteinsJournal of Molecular Biology, 1984